European Biotechnology Magazine Summer 2020 | Free Excerpt

ISSN 2364-2351 | A 60711 |

Life Sciences and Industry Magazine Summer Edition 2020 | Volume 19 | 20 €

Interview Pistoia Alliance data manager Ian Harrow on making life science data FAIR for the Age of AI.

T P R E E EXC

FRE

COVID-19

The EU strikes back Artificial Intelligence

Antimicrobials

Focus Corona

How progress in AI and biology is transforming how we live

The pharma industry commits to launch a €1bn VC fund for AMR

Who will provide the solutions for the pandemics of the future?

Don t prepare. Just be ready.

C2MAP-2000 – 1 method, 17 mins, 95 media components The C2MAP-2000 automates all steps from pretreatment to measurement without any human intervention. It simplifies the workflow for optimizing cell culture conditions. There is no need to prepare. Just be ready.

Complete LCMS solution for cell culture analysis combining the C2MAP-2000 pretreatment module with ultra-fast LCMS-8060

Monitoring of up to 95 components including amino acids, metabolites, sugars, vitamins and organic acids Changes at a glance with C2MAP-TRENDS viewer software visualizing temporal changes of components

Highly efficient through cutting culture media analysis time by 80 percent

www.shimadzu.eu/c2map

C2MAP-2000 – Complete LCMS solution

European Biotechnology | Summer Edition | Vol. 19 | 2020

Intro FREE EXCERPT

SARS-CoV-2 vaccines will not cure COVID-19 As the race for a SARS-CoV-2 vaccine increases, many people neglect the simple fact that, even if it is found and shown to be safe, it will not cure patients suffering from COVID-19. Once the virus has invaded the respiratory system of a patient, a vaccination is of little help. Moreover, vaccine development is often a very long process, and the production needs to supply doses for several billion people worldwide. Realistically, it will take many years, and it will cost billions of dollars. Until we have vaccinated the world and eradicated the virus, hundreds of thousands of people will likely die from COVID-19. That is why we need antiviral drugs in addition to vaccines. And, we need them quickly to treat severe COVID-19 cases and save lives today.

The development of novel drugs can take more than ten years from research to market. On short notice, the pharma industry tried to repurpose existing drugs, but many of them showed no significant benefits so far, with some even worsening the patient’s condition. Some recent trials demonstrated moderate progress in ameliorating inflammation symptoms in later stages, or interfering with the virus replication to improve the prognosis for patients, but none have yet the ability to stop the virus from infecting host cells. The high financial risk of new drug development and the uncertainty of the COVID-19 “market” led many players to postpone decisions. However, there is another hope in the battle against COVID-19. When our immune system responds to the infection, it generates a valuable resource for an antiviral drug – our own antibodies that neutralise the virus. Serum from convalescent donors achieved some positive effects, but this is a quite limited and undefined resource. The better alternative would be a recombinant, fully human, virus-neutralising antibody. This type of molecule could even reach the clinics much quicker than other drug types. Fully human antibodies are typically safe and well-tolerated. Moreover, development pathways for antibody drugs are well established, and, significantly, a vast large-scale antibody manufacturing infrastructure is available. Unlike vaccines, neutralising antibodies act immediately without delay and are hoped to cure COVID-19 in later stages, as well.

Due to the long halftime, antibodies can be even used as a “passive vaccine”, to protect risk groups and health care workers for a few weeks.

Picture: Verena Meier Fotografie

Dr Thomas Schirrmann is the CEO of YUMAB GmbH and Corat Therapeutics GmbH in Braun­schweig, Germany. He is a biochemist by training and completed his PhD in immunology.

He worked as a scientist and research group leader for 20 years and published more than 70 scientific articles in the fields of immunology, immunotherapy, and antibody technologies. In 2012/13, he founded YUMAB, which is dedicated to antibody drug development. In May 2020, YUMAB spun out Corat Therapeutics to bring a fast-track COVID-19 antibody program to clinical trials.

So, what is the challenge? Normally, with the neutralising antibody candidate in hand, one needs two to three years to start the first clinical trials in humans. Luckily, due to the pandemics’ pressure, it seems that all institutions are doing their best to significantly shorten this process. Thanks to a concerted effort, some antibody development programmes are already on their way, and they have been conceived and approved to take only a few months. For the benefit of the patients that will still populate our intensive care units for years to come, it is important to keep these programmes up and running and financially-supported, even if the first vaccine studies appear promising.

L

3

Contents

European Biotechnology | Summer Edition | Vol. 19 | 2020

FREE EXCERPT

Cover Story

16

COVID-19 therapies: The EU strikes back More than six months after a novel coronavirus in China first hit headlines, we’re staggering under the scope of the pandemic. How much energy and how many resources should we be pumping into vaccines, mass diagnostic testing or new therapeutics? Europe is making plans to bring production of some medicines back from Asia. Just one step in a strategy that could prove perfect or pointless, in a world that is continuing to batten down the hatches.

We look at some of the many measures that could make a difference.

Insight Europe

Regional News

6 European Greens fight over

‘new genetic engineering’ – and a revision of the EU’s GMO law

64 Northern Europe: Sweden, Denmark, Norway and Finland

8

Research project investigates traceability and market control of unintended spread from genomeedited agricultural products; Big Pharma flexes its muscles.

66 Southern Europe:

Italy, Spain and Greece

68 Central Europe:

Germany, Switzerland

and Austria

9

European Commission pledges an additional €4.9bn to fight COVID-19

70 Western Europe: France, Belgium, The Netherlands and the UK

10

Antimicrobial resistance is back on the global agenda: Industry launches €1bn Venture Capital fund

72 Eastern Europe:

Poland, Czech Republic and

Estonia

14 Industrial Biotechnology –

achieving a sustainable

green recovery

Economy 34

Interview: Federico Pollano, Senior Vice President of Global Business Development, Rentschler Biopharma SE

36 IP Flash

Science & Technology 58 Interview: AI in cancer Hartmut Juhl, CEO, Indivumed Group 62 Vital expertise in oncolytic virus production 82 Researchers begin clinical testing on a universal vaccine to rejuvenate immune systems in the elderly

Service

37 Market commentary 38 Euro Biotech Stocks 41 Update on clinical trials 44 EMA News

49 Biopeople 77 News from the SBA 78 New Products 80 Events 81 Company index 82 Encore

IMPRINT European Biotechnology (ISSN 2364-2351) is published quarterly by: BIOCOM AG, Lützowstr. 33–36, D-10785 Berlin, Germany, Tel.: +49-30-264921-0, Fax: +49-30-264921-11, Email: service@european-biotechnology.com, Internet: www.european-biotechnology.com; Publisher: Andreas Mietzsch; Editorial Team: Thomas Gabrielczyk (Editor in Chief), Derrick Williams (Co-editor), Sandra Wirsching, Uta Mommert; Advertising: Oliver Schnell, +49-30-2649-2145, Christian Böhm, +49-30-2649-2149, Andreas Macht, +49-30-2649-2154; Distribution: Lukas Bannert, +4930-2649-2148; Graphic Design: Michaela Reblin; Production editor: Benjamin Röbig; Printed at: Königsdruck, Berlin; European Biotechnology Life Sciences & Industry Magazine is only regularly available through subscription at BIOCOM AG. Annual subscription BIOCOM CARD Europe: €80 for private individuals (students €40) incl. VAT, €120 plus VAT for corporates. Prices includes postage & packaging.

Ordered subscriptions can be cancelled within two weeks directly at BIOCOM AG. The subscription is initially valid for one year. Subscriptions will be renewed automatically for one more year, respectively, unless they are cancelled at least six weeks before the date of expiry. Failures of delivery, which BIOCOM AG is not responsible for, do not entitle the subscriber to delivery or reimbursement of pre-paid fees.

Seat of court is Berlin, Germany. As regards contents: individually named articles are published within the sole responsibility of their respective authors. All material published is protected by copyright.

No article or part thereof may be reproduced in any way or processed, copied and proliferated by electronic means without the prior written consent of the publisher. Cover Photo: sdecoret/stock.adobe.com; ® BIOCOM is a registered trademark of BIOCOM AG, Berlin, Germany.

Picture: sdecoret/stock.adobe.com

4

Contents

European Biotechnology | Summer Edition | Vol. 19 | 2020

FREE EXCERPT

ARTIFICIAL INTELLIGENCE

Data Management

Editorial

Positive perception

Medicine – a new age Self-learning algorithms are growing common not only in oncology, and a flood of new publications suggests they already outperform trained experts in many areas of diagnosis. Pharma giants have cracked open the door to machines choosing drug candidates. AI is set to have a huge impact in the coming years on both health systems and patients.

60

Collecting FAIR data

Pictures: NIAID(below), pinkeyes/stock.adobe.com (upper left), Pistoia Alliance (middle), BIOCOM AG (right)

50

A survey conducted by the Pistoia Alliance found that AI in the life sciences is still being held back by data issues and skills shortages. We spoke with Ian Harrow, a Consultant at the Alliance, about how to improve data management in the field with help from a new toolkit that makes data Findable, Accessible, Inter­operable and Reusable – in brief: FAIR.

FOCUS COVID-19 23 24 26

28

29

30 32

Targeting coronaviruses A rapid test for pandemics Interview: Raimund Gabriel, CEO and Founder, MC Services Munich, Germany The end of partnering events as we know them Antiviral drugs for pandemic preparedness Sourcing reference products Defining the bioprocess early is key to quality control

Will the COVID-19 crisis prove to be a turning point for the acceptance of biotech in Europe? Until recently, a majority of EU citizens only had negative associations with biotechnology – GMOs are a case in point (see p. 6).

The novel coronavirus, however, is changing this mass perception dramatically (see p. 26). With the world desperate to put lockdowns behind as quickly as possible, biotech fields are the only ones to offer hope through possible solutions – whether in diagnostics, therapies or vaccines (see COVID-19 Special pp. 16–35).

And when biotech is no longer viewed as a threat, its platform technologies will bear economic fruit more quickly, and much more of it. At least, that's according to a new McKinsey study entitled "The Bio Revolution" (see p. 50). It predicts biotech could have €10 trillion in growth potential by 2040 – but only if it gains wider acceptance. Only then will sustainable methods in areas such as agriculture, AI-supported diagnostics and enzyme synthesis prevail, the study says.

With biotech’s help, will politicians be able to seize this opportunity to make Europe the most sustainable place on the planet? Or will governments prioritise preserving vested interests – a choice that will be paid for by our children’s children? We’ll only know when the pandemic has passed. But until then, there's plenty we can personally do to keep the vision alive.

Thomas Gabrielczyk Editor-in-Chief

5

AI

Digitally colored scanning electron micrograph of apoptotic cells (burgundy) heavily infected with SARS-CoV-2 virus particles (green), isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland (US).

European Biotechnology | Summer Edition | Vol. 19 | 2020

Pictures: xxx

16

COVID-19

European Biotechnology | Summer Edition | Vol. 19 | 2020

FREE EXCERPT

COVID-19 therapy – the EU strikes back Corona Crisis No one can yet predict with any certainty what strategies will prove most effective

against COVID-19. Along with upping production capacities for vaccines and diagnostics, European Union leaders are discussing plans to expand production of the first effective therapeutics. Under the German EU presidency, some production could be brought back from Asia.

F

or Andrea Ammon, Director of the European Centre for Disease Control (ECDC), the decline in the number of infections with the new SARS-CoV-2 coronavirus in most European countries is only a stage, not a victory. “I don’t want to draw a doomsday picture, but I think we have to be realistic.

The virus seems to be very well adapted to humans. Now is not the time to completely relax,” she said – just before a second wave of infection hit Israel.

be a COVID-19 vaccine, and no real idea how long development could take. Then there’s the question of how long it will protect recipients.

At a virtual expert briefing of the German biotech industry association BIO Deutsch­land, she suggested establishing a monitoring system by September that includes making diagnostics available in

Pictures: NIAID, NIH (left), ECDC (right)

Three-pronged strategy Experts like former FDA head Scott Gottlieb are predicting that a second wave could descend on Europe and the US this autumn, roughly two years before the European Medicines Agency (EMA) estimates a protective vaccine will be available for the broader population. While heavily funded vaccine coalitions have advanced the clinical development of potential jabs, and are busy ramping up capacities for potential mass production (see p. 18), there are a lot of open questions. For example, it’s unclear whether any of the current vaccine candidates in clinical testing will be able to prevent virus entry where it’s needed – at the mucous membranes in the upper respiratory tract.

According to HIV pioneer and Aicuris GmbH founder Helga Rübsamen-Schaeff “there’s no guarantee” that there will even

Dr. Peter Llewellyn-Davis CEO, Apeiron Biologics AG, Vienna, Austria

? !

hy is APN01 more specific for W the treatment of Covid-19 than other therapies?

APN01 is specific to treat Covid­19. It’s not a repurposed drug.

SARS and Sars-cov-2 use the same receptor to enter cells. An imitator of the ACE2 molecule, APN01 binds specifically to the virus, inhibits infection, and protects the lung.”

every doctor’s practice in the country, in order to to quickly identify infected people who have to be quarantined. She also recommended making therapies available that demonstrably alleviate the course of the two disease phases of COVID-19 – viremia and host immune response.

“Realistically, vaccine development will take many years, and will cost billions of dollars,” says Thomas Schirr­ mann. The CEO of antibody developer Yumab and CORAT Therapeutics GmbH told European Biotechnology that “until we have vaccinated the world and eradicated the virus, hundreds of thousands of people will likely die from COVID-19. That’s why we need antiviral drugs in addition to vaccines.”

Results from the UK’s Recovery trial demonstrate that approved drugs like dexa­m ethasone could provide a quick lifeline. The cheap anti-rheumatic cortico­ steroid (US$15/10-day course of treatment) saved the life of one in eight ventilated COVID-19 patients compared to the standard-of-care. On the other hand, the antiviral HIV treatment lopinavirritonavir and malaria medicine hydroxy­ chloroquine failed. The first clinical results from IL-6 blockers like Sanofi-Regeneron’s saralimumab or Roche’s tocilizumab – which might help control late-stage cytokine storms – showed mixed results […]

›› Read the full story in the printed issue.

17

AI

Patient data grows more readable for machines by the day. Has the Biohacking Era dawned with the advent of Big Medicine? There’s no longer a way to get around machine analysis of personal medical information, because it has the potential to significantly improve diagnosis, therapy and healthcare decisions. Under the FAIR guidelines, the biopharma industry is taking an approach to data acessibility in AI-driven research that seeks to strike a balance with protecting patient data.

European Biotechnology | Summer Edition | Vol. 19 | 2020

Pictures: xxx

50

AI

European Biotechnology | Summer Edition | Vol. 19 | 2020

FREE EXCERPT

My robot doctor – a new age in medicine Deep learning The machines take over – it’s the backdrop for countless science fiction novels.

Will it happen first in medicine? Self-learning algorithms are already helping oncologists analyse Big Data, and a flood of new publications suggest they already outperform trained experts in image-, sequencingand clinical data-based diagnosis. Pharma giants have cracked open the door to machines choosing drug candidates, and are using them to analyse deficient signaling pathways that lead to cancer and other health threats. So what impact will AI have on health systems – and patients?

Pictures: pinkeyes/stock.adobe.com (left), Indivumed Group (right)

I

n tandem with accelerating developments in computing, data processing, and artificial intelligence (AI)-driven analytics, advances in the biological sciences are fueling a new wave of innovation that could have a significant impact in a wide range of sectors – from healthcare and agriculture to consumer goods and energy. That’s the outlook that sets the tone for the new McKinsey Global Institute report “The Bio Revolution”. According to senior partner Matthias Evers and his co-authors, transformative “new methodologies, including automation, machine learning, and proliferating biological data are enhancing discovery, throughput and productivity in R&D.” Self-learning algorithms that allow both automatic interpretation and comparison of next-generation sequencing (NGS) as well as diagnostic imaging data – and which additionally integrate the current knowledge on coronaviruses – are not just being used to find drugs and targets that could help arrest the current COVID-19 pandemic (see interview pp. 60-61). They also have the potential to improve productivity across the entire diagnostic and therapeutic pipeline.

And some applications go far beyond that. According to the report, in human health alone, at least 45% of the global disease burden could be addressed if existing scientific data were findable, acces-

sible, interoperational and reusable (FAIR) by machines, particularly in an automated manner. Depending on how quickly the technologies are adopted, the authors estimate economic potential among all biologic applications in the next 10 to

Prof. Dr. HaRtmut Juhl Founder and CEO Indivumed Group, Hamburg, Germany

?

How important do you think self-learning algorithms will be to cancer diagnosis in the future?

!

Deciphering the biological complexity of cancer is the future of precision oncology. AI-based algorithms are essential for achieving this goal, because they enable highly efficient drug development and patient diagnostics for personalised medicine.

20 years of US$2tn-$4tn annually (see Fig. 1, p. 52).

Stripping disease to its basics Just as with human intelligence, there’s no single accepted definition for AI. In simple terms, however, it includes all attempts to transfer human learning and thinking to a computer system so it can solve problems independently. Normal, rule-based systems written by programmers are not AI, because they are for example unable to recognise an image of the same person in fog, rain, backlight, with a beard or clean-shaven, etc. AI algorithms, on the other hand, can learn to distinguish people from existing images or data. And they can do the same for tumours or tissues. By applying the rules they learn to billions of new images, they can recognise patterns in Big Data sets. The same applies to other analytical data from the life sciences laboratory. The combination of machinereadable Big Data and its analysis via AI therefore offers hitherto unimaginable possibilities for the life sciences. In the analysis of both structured and unstructured data, self-learning algorithms are far superior to rule-based software […]

›› Read the full story in the printed issue.

51

WESTERN EUROPE

European Biotechnology | Summer Edition | Vol. 19 | 2020

FREE EXCERPT

Citizens alone at home

Beam me up COVID-19 After the chimpanzee

adenoviral COVID-19 vaccine ChAdOx1 nCoV-19 – developed at the University of Oxford by Sarah Gilbert and Andrew Pollard and produced by Halix BV – successfully passed Phase I safety testing, AstraZeneca plc acquired the worldwide marketing rights. In Phase II/III trials, which started enrolment of up to 10,260 volunteers at the end of May, the immunogenicity and in vitro virus neutralisation capability of the jab, renamed AZD-1222, and the MenACWY ‘control’ vaccine is now to be compared.

In June, Lyon-based vaccine and gene therapy vector CDMO Novasep SA announced that it will contribute to the production for up to 300 million doses of AZ1222 ordered by the Inclusive Alliance for Vaccines (IAV), consisting of France, Germany, Italy and the Netherlands. But the Alliance will also make AZD-1222 available for other countries in Europe starting from autumn.

In its Seneffe (Belgium) facilities, the CDMO will produce the active substance of the vaccine, while Emergent Bio­s olution Inc will be AstraZeneca’s manufacturing partner in the US. There, AZ-1222 was selected for a €1.2bn funding within US President Donald Trump’s COVID vaccine accelerator “Operation Warp Speed” that is aimed to provide 400 million doses until September 2020. Through an EU emergency fund of €2.3bn, the European Commission has the mandate to purchase up to six different COVID-19 vaccines for all member states.

L

Antibody testing An international research consortium has found initial evidence that SARS-CoV-2 antibody tests are only useful for population-based analyses. This is no good message for policymakers willing to relax social distancing measures based on immunity passports or antibody titers against the spike- and nucleocapsid proteins of SARS-CoV-2: In Science Immunology, Juliet Bryant from Fondation Mérieux in Lyon, France, and colleagues highlight the potential power of population-level serological, or antibody testing to provide snapshots of infection history and immunity in populations as the COVID-19 pandemic progresses. In contrast, they emphasise the risks of using current serological tests to assess individual immunity to the SARS-CoV-2 virus.

While the World Health Organization WHO recommends restricting such antibody testing to research use only, scientists here argue that these tests – even with moderate sensitivity and specificity

levels – could provide highly valuable information to address critical public health questions, such as when to relax stay-athome orders or school closures.

In theory, antibody tests can examine whether or not a person has ever been exposed to a certain virus. However, what SARS-CoV-2 antibody test results mean for protection and immunity is still poorly understood. Thus, as tools to issue “immune passports” that certify an individual’s immunity, current serological tests were insufficient and even harmful, the authors write; the tests would, in fact, need near-perfect specificity to provide a reliable gauge of immune protection. By contrast, as tools to ascertain populationlevel epidemiological trends, and in conjunction with PCR testing, serological surveys could help officials estimate the risk of future waves of disease, measure the impact of interventions, and may provide a less biased picture of infection fatality rate than PCR testing of viral RNA. L

Evox Therapeutics has isolated and analysed exosomes targeting different tissues.

Struggling for market shares OncoLogy Dutch formulation specialist SeraNovo BV has extended the exist-

ing licence contract with US kinase blocker expert Carna Biosciences, Inc. Under a new contract, the companies will co-develop an oral GRAS excipient-based formulation to increase the oral bioavailability of a preclinical pipeline product of Carna BioSciences.

L

Picture: SeraNova BV

70

European Biotechnology | Summer Edition | Vol. 19 | 2020

WESTERN EUROPE FREE EXCERPT

New vesicular vehicle

News Bone growth

Drug delivery Evox Therapeutics Ltd has licenced its exosome-based RNAi/antisense RNA delivery technology to Eli Lilly to target selected brain/ CNS disorders. Lilly paid US$20m upfront and US$10m per convertible bond.

Additionally, Evox Therapeutics is eliglible to receive up to US$1.2bn in development, regulatory and commercial milestone payments. Under the contract, Eli Lilly will provide antisense oligonucleotides directed against five, not speci-

fied yet, neurological drug targets. Evox Therapeutics will functionalise exosomes in order to achieve brain/CNS targeting, drug loading and analytics and some in vitro assay development, as well as material supply for initial in vivo studies. Lilly will have the right to opt in after preclinical proof of concept and will receive the exclusive right to commercialise all licenced drug candidates. Evox will receive tiered royalties on net sales if a product makes it to the market.

L

Picture: Evox Therapeutics Ltd

Money for CBD developers Finance In June Óskare Capital SAS launched the first European fund particularly dedicated to EU companies in the medical cannabinoid industry: Óskare Fund I targets next-generation cannabinoid therapies and related industry infrastructure, leveraging the expertise and track record of the founding team in medicine, engineering, chemistry, venture capital, and intellectual property.

“I am convinced that Europe has the optimal regulatory and research environment to build the future key players in the global medical cannabinoid industry,” said Bruce Linton, co-founder and non-executive Chairman of Óskare Capital SAS and former CEO and founder at Canopy Growth. The fund will invest in a di-

versified portfolio of companies with disruptive technology and strong barriers to entry. The team is supported by a highly experienced senior advisory board that provides critical expertise and expands its network. Medical grade cannabinoidbased products are already approved and used in Europe to treat conditions such as epilepsy, multiple sclerosis and chronic pain. Now the science and the medical community are driving opportunities in human as well as animal health and wellness. The fund will invest in the entire value chain as well as look to valorise hemp and cannabis biomass for new sustainable material applications. A first investment has been made in Denmark’s Octarine Bio. L

Belgian Bone Therapeutics SA has secured €11m to foster the development of its late-stage pipeline candidates. The company said it will use the proceeds to advance two key assets of its allogeneic cell therapy platform, ALLOB and JTA-004, which have both completed Phase IIa tests. The financing operation consists of a €4.75m bridge loan, €1.26m in equity private placement by existing shareholders and, on an as-needed basis, a €4.99m private placement of convertible bonds.

Subject to the completion of the current financing operation, supporting the company’s further development and strengthen its balance sheet, Bone Therapeutics expects to have a runway into Q1/2021.

Adding compounds For years, French Carbios SAS has worked to set up a process that effectively depolymerises polyethylen­ terephtalate (PET) waste, which makes one-fifth of the 359 million tons of mostly non-degradable plastics produced annually. In April, details of the process were published.

While mechanical properties are lost during the physico-mechanical approaches applied today to degrade PET, Carbios’ optimised bacterial hydrolase/depolymerase leads to over 90% of PET recovery by a process that lasts 10 hours and is to be scaled up by 2021. The company’s process provides recycled PET that exhibits the same properties as petrochemical PET and can be produced from enzymatically depolymerized PET waste, thereby contributing towards the concept of a circular PET economy.

71

80

Company Index

European Biotechnology | Summer Edition | Vol. 19 | 2020

FREE EXCERPT

A AbbVie Inc. (USA) . . . . . . . . . . . . . . . 56, 64 Accord Healthcare S.L.U. (ES) . . . . . . . . . 44 Adaptive Biotechnologies (USA). . . . . . . . 56 AI VIVO (UK). . . . . . . . . . . . . . . . . . . . . . 54 AiCuris GmbH & Co KG (DE). . . . . . . . . . 17 Amazon (USA). . . . . . . . . . . . . . . . . . . . . 15 Apeiron Biologics AG (AT) . . . . . . . . . 17, 23 Aptamer Group Ltd (UK). . . . . . . . . . . . . . 20 Arya Sciences Acquisitions(USA) . . . . . . . 69 AstraZeneca AB (SE/UK). . . . . . 3, 18, 20, 41 Atriva Therapeutics GmbH (DE) . . . . . . . . 29 Austria Economic Service Company. . . . . 23 AveXis EU Ltd. (IRL). . . . . . . . . . . . . . . . . 44

F

B BASF (DE). . . . . . . . . . . . . . . . . . . . . . 14, 15 Bavarian Nordic (DK). . . . . . . . . . . . . . . . 43 Bayer AG (DE) . . . . . . . . . . . . . . . 10, 56, 65 Bioascent Discovery Ltd (UK). . . . . . . . . . 49 BIOCOM AG (DE) . . . . . . . . . . . . . . . . . . 40 BioFIT & MedFIT 2020 (DE). . . . . . . . 73, 81 Biognosys AG (CH). . . . . . . . . . . . . . . . . . 49 BioNTech SE (DE). . . . . . . . . . . . . 18, 37, 69 BioVersys AG (CH). . . . . . . . . . . . . . . . . . 10 Boehmert & Boehmert (DE) . . . . . . . . 36, 63 Boehringer Ingelheim (DE). . . . . . . . . 10, 13 Bone Therapeutics (B). . . . . . . . . . . . . . . . 71 Bosch Healthcare (DE). . . . . . . . . . . . . . . 22

Gilead Sciences Internation (USA) . . . . . . 75

C Calliditas Therapeutics AB (SE). . . . . . . . . 65 Canopy Growth (CDN). . . . . . . . . . . . . . . 71 Carbios SAS (F). . . . . . . . . . . . . . . . . . 14, 71 Carna Biosciences Inc. (USA). . . . . . . . . . 70 Cassiopea SPA (IT) . . . . . . . . . . . . . . . . . . 66 Celgene Europe BV (NL). . . . . . . . . . . . . . 44 Centogene AG (DE) . . . . . . . . . . . . . . . . . 22 CORAT Therapeutics GmbH (DE). . . . . 3, 17 Cosmo Pharmaceuticals (IT). . . . . . . . 66, 69 Covestro Deutschland AG. . . . . . . . . . . . . 15 Cowen Inc. (USA). . . . . . . . . . . . . . . . . . . 37 CSL Behring GmbH (DE) . . . . . . . . . . . . . 65 CureVac AG (DE). . . . . . . . . . . . . . . . . . . 18 D Deep Lens Inc. (USA). . . . . . . . . . . . . . . . 53 Deinove SA (F). . . . . . . . . . . . . . . . . . . . . 49 DGPharMed (DE). . . . . . . . . . . . . . 53, 59,81 E Eli Lilly (USA). . . . . . . . . . . . . . . . . . . 10, 71 Emergent Biosolutions (USA) . . . . . . . . . . 41 Eppendorf Bioprocess Center Eur. (DE). . . . . 55 EUROIMMUN AG (DE) . . . . . . . . . . . . . . 33 EuropaBio (B). . . . . . . . . . . . . . . . . . . . . CP3 European Biotechnology Network (B). . . . 61 Evox Therapeutics Ltd (UK). . . . . . . . . 49, 71

faCellitate (DE). . . . . . . . . . . . . . . . . . . . . 79 Faron Pharmaceuticals Oy (FIN). . . . . . . . 65 FGK Clinical Research GmbH (DE). . . . . . 43 Fördergesellschaft IZB (DE). . . . . . . . . 45–48 Fosun Pharma (CN). . . . . . . . . . . . . . . . . . 18 Fraport GmbH (DE). . . . . . . . . . . . . . . . . . 22 G Galapagos NV (B). . . . . . . . . . . . . . . . . . . 72 GBA Group Pharma (DE). . . . . . . . . . 30, 35 GC Pharma. . . . . . . . . . . . . . . . . . . . . . . . 65 GE Healthcare Ltd. (UK). . . . . . . . . . . . . . 53 Genmab A/S (DK). . . . . . . . . . . . . . . . 37, 64 GlaxoSmithKline (UK) . . . . . . . . . . . . . . . 10 GNA Biosolutions (DE). . . . . . . . . . . . 21, 24 Grifols SA (ES) . . . . . . . . . . . . . . . . . . . . . 65 H Halix B.V. (NL). . . . . . . . . . . . . . . . . . 41, 70 I

N Nanome.ai (USA). . . . . . . . . . . . . . . . . . . 54 Nicox S.A. (F). . . . . . . . . . . . . . . . . . . . . . 43 Nova BIomedical GmbH (CH/D) . . . . . 9, 79 Novartis Europharm Ltd. (UK). . . . . . . . . . 44 Novasep SA (F). . . . . . . . . . . . . . . . . . . . . 70 Novavax Inc. (USA) . . . . . . . . . . . . . . . . . 18 Novo Holdings (DK). . . . . . . . . . . . . . . . . 10 Novo Nordisk A/S (DK). . . . . . . . . . . . . . . 42 O Octarine Bio (DK). . . . . . . . . . . . . . . . . . . 71 Oncoradiomics BV (B). . . . . . . . . . . . . . . 56 Orphan Biovitrum AB (SE) . . . . . . . . . . . . 65 Oskare Capital SAS (F). . . . . . . . . . . . . . . 71 P Paion AG (DE). . . . . . . . . . . . . . . . . . . . . . 69 Pepperprint GmbH (DE). . . . . . . . . . . . . . 25 Pfizer (USA). . . . . . . . . . . . . . . . . 10, 18, 69 PharmaMar S.A. (ES). . . . . . . . . . . . . . . . . 66 Pivotal S.L. (ES). . . . . . . . . . . . . . . . . . . . . 41 Polpharma Biologics S.A. (PL). . . . . . . . . GP4 Poxel SA (F) . . . . . . . . . . . . . . . . . . . . . . . 41

Immatics Biotechnologies AG (DE). . . . . . 69 Immunovative Therapies Ltd (IL). . . . . 22, 74 Indivumed GmbH (DE). . . . . . 51, 53, 57, 58 Innophore GmbH (AT). . . . . . . . . . . . . . . 69 Inovio Pharmaceuticals Inc. (USA). . . . . . 18 Insilico Medicine (USA). . . . . . . . . . . . . . 54 Integumen Ltd (UK) . . . . . . . . . . . . . . . . . 20 Ipsen Pharmaceuticals S.A. (F) . . . . . . . . . 49

Q/R Quest Diagnostics Inc. (USA). . . . . . . . . . 20 Randox Life Sciences (UK). . . . . . . . . . . . 22 RauCon GmbH & Co. KG (DE). . . . . . 32, 75 Rentschler Biopharma (DE). . . . . . 11, 34, 64 Roche (CH). . . . . 10, 17, 20, 42, 53, 56, 59, 61 Ryvu Therapeutics SA (PL) . . . . . . . . . . . . 72

Izana Bioscience (UK) . . . . . . . . . . . . . . . 41 J Janssen-Cilag International NV (B) . . . . . . 44 Jazz Pharmaceuticals plc (IRL) . . . . . . . . . 66 L Lufthansa AG (DE) . . . . . . . . . . . . . . . . . . 22 LuinaBio (AUS). . . . . . . . . . . . . . . . . . . . . . 7 M Mac Brooks Exhibitions Ltd. (UK). . . . . . . 81 MaaT Pharma (F) . . . . . . . . . . . . . . . . . . . 49 MC Services AG (DE). . . . . . . . . . . . . 26, 31 Merck & Co. (USA). . . . . . . . . . . . . . . . . . 72 Merck KGaA (DE). . . . . . . . . . . . . 10, 41, 43 Merck Millipore Sigma (USA). . . . . . . . . . 19 Mirror Biologics Inc.. . . . . . . . . . . . . . . . . 74 MLM Medical Labs GmbH (DE). . . . . . . . 67

S/T Sanofi-Aventis Group (F). . . . . . . . . . . . . . 44 SeraNovo B.V. (NL). . . . . . . . . . . . . . . . . . 70 SGS Belgium NV (B). . . . . . . . . . . . . . . . . 27 Shimadzu (DE). . . . . . . . . . . . . . . . . . . . CP2 Shire plc (IRL). . . . . . . . . . . . . . . . . . . . . . 64 Sinovac Biotech (CN). . . . . . . . . . . . . . . . 18 Sobi AB (SE). . . . . . . . . . . . . . . . . . . . . . . 65 SOM Biotech SpA (ES) . . . . . . . . . . . . . . . 66 Staidson Biopharmaceuticals (CN). . . . . . 41 The Hyve (NL) . . . . . . . . . . . . . . . . . . 56, 61 U/V UCB SA (B). . . . . . . . . . . . . . . . . . . . . . . . 42 Valneva SE (F). . . . . . . . . . . . . . . . . . . . . . 37 Vaxxim AG (CH/DE). . . . . . . . . . . . . . . . . 43 Vetter Pharma International (DE). . . . . . . . 41 Vibalogics GmbH (DE). . . . . . . . . . . . 59, 62 Vienna Business Agency (AT) . . . . . . . . . . 23

Modern Biosciences plc (UK). . . . . . . . . . 18 MSD Sharp & Dohme (USA). . . . . . . . . . . 10 Mylan IRE Healthcare Ltd. (IRL) . . . . . . . . 44 MYR GmbH (DE). . . . . . . . . . . . . . . . . . . 44

Y/Z Yumab GmbH (DE). . . . . . . . . . . . . . . . 3, 17 Zelluna Immunotherapies AS (NO). . . . . . 64

l a t i g i D Europe’s Leading Event on Industrial Biotechnology and the Bioeconomy 5 – 9 October 2020 · Live and on demand

Advancing the Green Economy with biotech innovation

June

The #EFIB2020 programme will focus on different indus-

July

try sectors and business areas. Each of the topics will be highlighted with insights, news and a pre-event webinar on sustainability challenges and opportunities after COVID-19.

Additionally, virtual 1:1 meetings will be possible 24-hours/ day throughout the whole conference week.

Explore #EFIB2020 www.efibforum.com

Organised by

Supporting Partner

TOPIC CALENDAR

› Topic: Green. Circular. Sustainable › Topic: Food, Feed & Nutrition August

› Topic: Fashion & Textiles September

› Topic: Financing & Investing › Topic: Materials & Packaging October

› Topic: Bioprocesses & Technologies › Digital EFIB 2020 week:

All topics + 1:1 Partnering Meetings

INTEGRATED BIOLOGICS DEVELOPMENT TO SUPPORT YOU FROM DISCOVERY TO COMMERCIAL SUPPLY ŶƟďŽĚLJ ŝƐĐŽǀĞƌLJ

We have now integrated our Dutch based subsidiary, Bioceros, fully into Polpharma Biologics, enabling ƵƐ ƚŽ ŽīĞƌ ƚŚĞ ĐŽŵƉůĞƚĞ ƐƉĞĐƚƌƵŵ ŽĨ ƐĞƌǀŝĐĞƐ ĨƌŽŵ discovery to commercial supply.

ŶƟďŽĚLJ KƉƟŵŝnjĂƟŽŶ

The change means Polpharma Biologics can now ĂĚĚŝƟŽŶĂůůLJ ŽīĞƌ ƚŚĞ ĚĞǀĞůŽƉŵĞŶƚ ŽĨ ŚŝŐŚ ƋƵĂůŝƚLJ ĂŶĚ ŚŝŐŚ LJŝĞůĚ ĐĞůů ůŝŶĞƐ ƚŚƌŽƵŐŚ ŽƵƌ ƉƌŽƉƌŝĞƚĂƌLJ ƉůĂƞŽƌŵ CHOBC®, as well as comprehensive discovery, process ĚĞǀĞůŽƉŵĞŶƚ ĂŶĚ ĂŶĂůLJƟĐĂů ĐĂƉĂďŝůŝƟĞƐ ĨŽƌ ƚŚĞ development of novel biologics and biosimilar.

&ŽƌŵƵůĂƟŽŶ ĞǀĞůŽƉŵĞŶƚ

www.polpharmabiologics.com

Cell Line Development ŶĂůLJƟĐĂů ĞǀĞůŽƉŵĞŶƚ ĂŶĚ ŚĂƌĂĐƚĞƌŝnjĂƟŽŶ ;h^W ĂŶĚ ^WͿ

WƌŽĐĞƐƐ ^ĐĂůĞͲƵƉ ůŝŶŝĐĂů ^ ĂŶĚ W DĂŶƵĨĂĐƚƵƌŝŶŐ WƌŽĐĞƐƐ sĂůŝĚĂƟŽŶ ĂŶĚ ŽŵŵĞƌŝĐĂů ^ DĂŶƵĨĂĐƚƵƌŝŶŐ &ŝůů Θ &ŝŶŝƐŚ ;ǀŝĂů͕ W&^͕ ĐĂƌƚƌŝĚŐĞƐ͕ ůŝƋƵŝĚ ĂŶĚ ůLJŽƉŚŝnjĞĚ ĨŽƌŵƵůĂƟŽŶƐͿ